Canada’s brand-name pharmaceutical companies are pushing back against a plan to overhaul Canada’s drug-pricing regulator, saying they are keen to forge a compromise that would reduce prices, but not to a degree that could be “crippling” for the industry.
The president of Innovative Medicines Canada (IMC), which represents more than 45 companies, is planning to warn in a speech on Tuesday that her industry could struggle to invest in high-risk innovation, hire top talent and run local clinical trials if companies are forced to slash their prices too deeply, too quickly.
Read more at The Globe and Mail
Leave a Reply